Stock listing
OTC:SRNE Sorrento Therapeutics, Inc. Stock
Follow Sorrento Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · OTC:SRNE
$0.0004 USD +0.0001 (+33.3%)
Close on Nov 20, 2026
- Day range
- $0.0001 – $0.0004 USDNov 20, 2026
- Volume
- 441,967 sharesNov 20, 2026
- Market cap
- $220,512 USDAt the close on Nov 20, 2026 · price × 551.3M shares outstanding
- 52-week range
- $0.0001 – $0.0100 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $64 USDMedian day 73,281 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:SRNE · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.0004 | +0.0001 | +33.3% | $0.0003 | $0.0004 | $0.0001 | 441,967 | |
| $0.0003 | -0.0002 | -40.0% | $0.0005 | $0.0005 | $0.0003 | 465,766 | |
| $0.0005 | +0.0002 | +66.7% | $0.0004 | $0.0006 | $0.0003 | 279,226 | |
| $0.0003 | 0.0000 | 0.0% | $0.0006 | $0.0006 | $0.0003 | 320,830 | |
| $0.0003 | 0.0000 | 0.0% | $0.0003 | $0.0046 | $0.0003 | 578,658 | |
| $0.0003 | 0.0000 | 0.0% | $0.0003 | $0.0003 | $0.0003 | 69,285 | |
| $0.0003 | 0.0000 | 0.0% | $0.0003 | $0.0004 | $0.0003 | 168,407 | |
| $0.0003 | 0.0000 | 0.0% | $0.0003 | $0.0004 | $0.0001 | 1,372,640 | |
| $0.0003 | 0.0000 | 0.0% | $0.0003 | $0.0010 | $0.0003 | 121,583 | |
| $0.0003 | 0.0000 | 0.0% | $0.0003 | $0.0004 | $0.0003 | 203,787 | |
| $0.0003 | 0.0000 | 0.0% | $0.0003 | $0.0003 | $0.0003 | 51,182 | |
| $0.0003 | 0.0000 | 0.0% | $0.0003 | $0.0003 | $0.0003 | 217,568 | |
| $0.0003 | 0.0000 | 0.0% | $0.0003 | $0.0003 | $0.0003 | 27,691 | |
| $0.0003 | 0.0000 | 0.0% | $0.0003 | $0.0004 | $0.0003 | 16,472 | |
| $0.0003 | 0.0000 | 0.0% | $0.0003 | $0.0005 | $0.0003 | 234,692 | |
| $0.0003 | 0.0000 | 0.0% | $0.0003 | $0.0050 | $0.0003 | 10,988 | |
| $0.0003 | -0.0004 | -57.1% | $0.0003 | $0.0005 | $0.0003 | 17,723 | |
| $0.0007 | +0.0006 | +600.0% | $0.0001 | $0.0007 | $0.0001 | 403,304 | |
| $0.0001 | -0.0001 | -50.0% | $0.0001 | $0.0002 | $0.0001 | 31,767 | |
| $0.0002 | +0.0001 | +100.0% | $0.0002 | $0.0002 | $0.0001 | 72,025 | |
| $0.0001 | -0.0002 | -66.7% | $0.0002 | $0.0010 | $0.0001 | 30,712 | |
| $0.0003 | +0.0001 | +50.0% | $0.0001 | $0.0046 | $0.0001 | 8,917 | |
| $0.0002 | -0.0006 | -75.0% | $0.0001 | $0.0020 | $0.0001 | 28,126 | |
| $0.0008 | +0.0006 | +300.0% | $0.0002 | $0.0029 | $0.0002 | 57,250 | |
| $0.0002 | -0.0003 | -60.0% | $0.0001 | $0.0002 | $0.0001 | 28,501 | |
| $0.0005 | 0.0000 | 0.0% | $0.0005 | $0.0010 | $0.0005 | 29,020 | |
| $0.0005 | +0.0003 | +150.0% | $0.0005 | $0.0010 | $0.0005 | 51,244 | |
| $0.0002 | -0.0001 | -33.3% | $0.0001 | $0.0006 | $0.0001 | 46,016 | |
| $0.0003 | -0.0003 | -50.0% | $0.0001 | $0.0006 | $0.0001 | 19,896 | |
| $0.0006 | -0.0002 | -25.0% | $0.0008 | $0.0010 | $0.0001 | 149,142 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 88,510 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0010 | $0.0008 | 78,361 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 39,275 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 180,129 | |
| $0.0008 | 0.0000 | 0.0% | $0.0005 | $0.0008 | $0.0005 | 143,522 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 22,761 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 92,792 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0010 | $0.0008 | 66,783 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 35,101 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 35,800 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 13,898 | |
| $0.0008 | +0.0003 | +60.0% | $0.0005 | $0.0009 | $0.0005 | 21,117 | |
| $0.0005 | 0.0000 | 0.0% | $0.0005 | $0.0008 | $0.0005 | 178,456 | |
| $0.0005 | 0.0000 | 0.0% | $0.0004 | $0.0005 | $0.0004 | 132,165 | |
| $0.0005 | +0.0002 | +66.7% | $0.0001 | $0.0005 | $0.0001 | 65,381 | |
| $0.0003 | -0.0001 | -25.0% | $0.0004 | $0.0008 | $0.0001 | 116,109 | |
| $0.0004 | 0.0000 | 0.0% | $0.0006 | $0.0006 | $0.0004 | 40,687 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0006 | $0.0004 | 79,548 | |
| $0.0004 | 0.0000 | 0.0% | $0.0006 | $0.0006 | $0.0004 | 88,787 | |
| $0.0004 | 0.0000 | 0.0% | $0.0006 | $0.0006 | $0.0004 | 64,522 | |
| $0.0004 | 0.0000 | 0.0% | $0.0006 | $0.0006 | $0.0004 | 73,281 | |
| $0.0004 | -0.0001 | -20.0% | $0.0004 | $0.0006 | $0.0004 | 33,800 | |
| $0.0005 | +0.0001 | +25.0% | $0.0006 | $0.0006 | $0.0004 | 54,942 | |
| $0.0004 | -0.0002 | -33.3% | $0.0005 | $0.0006 | $0.0004 | 129,160 | |
| $0.0006 | 0.0000 | 0.0% | $0.0090 | $0.0100 | $0.0006 | 501,682 | |
| $0.0006 | 0.0000 | 0.0% | $0.0001 | $0.0006 | $0.0001 | 26,035 | |
| $0.0006 | 0.0000 | 0.0% | $0.0006 | $0.0011 | $0.0006 | 91,492 | |
| $0.0006 | 0.0000 | 0.0% | $0.0006 | $0.0012 | $0.0006 | 192,863 | |
| $0.0006 | +0.0001 | +20.0% | $0.0009 | $0.0015 | $0.0006 | 88,266 | |
| $0.0005 | 0.0000 | 0.0% | $0.0005 | $0.0006 | $0.0005 | 26,838 | |
| $0.0005 | 0.0000 | 0.0% | $0.0005 | $0.0006 | $0.0005 | 26,750 | |
| $0.0005 | -0.0004 | -44.4% | $0.0004 | $0.0013 | $0.0004 | 103,292 | |
| $0.0009 | +0.0002 | +28.6% | $0.0005 | $0.0010 | $0.0005 | 135,982 | |
| $0.0007 | -0.0001 | -12.5% | $0.0008 | $0.0014 | $0.0006 | 332,415 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0013 | $0.0008 | 88,367 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0050 | $0.0008 | 39,050 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 166,464 |
Splits
3 splits since 2007 · OTC:SRNE · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-25 | Consolidation | |
| 1-for-10 | Consolidation | |
| 1-for-20 | Consolidation |
- Ticker
- OTC:SRNE
- Asset type
- Stock
- Exchange
- OTC
- Currency
- USD
Sorrento Therapeutics, Inc. on 6ix
- Decks
- 41 decks · latest Aug 1, 2023
Valuation
price Nov 20, 2026
- Enterprise value
- No statements on 6ix yet
- P/E
- No statements on 6ix yet
- EV/sales
- No statements on 6ix yet
- EV/EBITDA
- No statements on 6ix yet
- Price/book
- No statements on 6ix yet
- Gross margin
- No statements on 6ix yet
- Operating margin
- No statements on 6ix yet
- Net margin
- No statements on 6ix yet
- Debt to equity
- No statements on 6ix yet
- Beta vs S&P 500
- 1.32
Team and board
Officers
| Officer | Role |
|---|---|
| Henry Ji | Chairman, President and CEO |
| John Waldheim | Executive Director, Government Affairs |
| Scott Schaus | Chief Technology Officer |
Board
| Director | Role |
|---|---|
| Henry Ji | Chairman, President and CEO |
| John Waldheim | Executive Director, Government Affairs |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Dec 31, 2025 | Feb 25, 2026 | −31.3% |
| Quarter to Sep 30, 2025 | Nov 28, 2025 | −38.6% |
| Quarter to Jun 30, 2025 | Aug 29, 2025 | −16.7% |
| Quarter to Mar 31, 2025 | May 30, 2025 | −23.5% |
| Quarter to Dec 31, 2024 | Feb 26, 2025 | 0.0% |
| Quarter to Sep 30, 2024 | Nov 29, 2024 | −16.7% |
| Quarter to Jun 30, 2024 | Aug 13, 2024 | +23.1% |
| Quarter to Mar 31, 2024 | May 7, 2024 | −15.6% |
| Quarter to Dec 31, 2023 | Feb 28, 2024 | +1.1% |
| Quarter to Sep 30, 2023 | Nov 3, 2023 | +12.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2023 | Aug 14, 2023 | +6.7% |
| Q1 2023 | May 15, 2023 · After close | +3.1% |
| Q4 2022 | Mar 9, 2023 | −6.0% |
| Q3 2022 | Nov 8, 2022 · After close | −4.1% |
| Q2 2022 | Aug 15, 2022 · After close | −8.4% |
| Q1 2022 | May 5, 2022 · After close | −5.0% |
| Q4 2021 | Mar 11, 2022 · After close | −8.3% |
| Q3 2021 | Nov 5, 2021 · After close | −0.7% |
| Q2 2021 | Aug 6, 2021 · After close | +4.2% |
| Q1 2021 | May 5, 2021 · After close | −4.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Presentation (August 2023) | 9 slides | Aug 1, 2023 | |
| SPAC Merger (March 2022) | SPAC merger | 21 slides | Mar 18, 2022 |
| Technical Presentation (January 2022) | Technical | 13 slides | Jan 21, 2022 |
| SPAC Merger (December 2021) | SPAC merger | 57 slides | Dec 13, 2021 |
| Technical Presentation (November 2021) | Technical | 9 slides | Nov 29, 2021 |
| Investor Presentation (September 2021) | Investor deck | 37 slides | Sep 13, 2021 |
| Corporate Update (August 2021) | Corporate update | 14 slides | Aug 9, 2021 |
| Investor Presentation (January 2021) | Investor deck | 36 slides | Jan 11, 2021 |
| Investor Presentation (November 2020) | Investor deck | 32 slides | Nov 17, 2020 |
| Investor Presentation (February 2020) | Investor deck | 40 slides | Feb 27, 2020 |
All 41 decks
Financials
Annual, in USD
Income statement
| Line | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 62.8M | 52.9M | 40.0M | 31.4M | 21.2M | 151.9M | 8.15M | 4.59M | 3.83M | 460.1K |
| Cost of revenue | 33.5M | 13.0M | 9.94M | 12.2M | 7.06M | 3.94M | 811.0K | 1.95M | 2.04M | 4.44K |
| Gross profit | 29.4M | 39.9M | 30.0M | 19.2M | 14.1M | 147.9M | 7.34M | 2.64M | 1.78M | 455.7K |
| Research and development | 221.2M | 206.9M | 111.3M | 106.9M | 77.0M | 55.5M | 42.2M | 31.3M | 24.0M | 9.02M |
| Selling, general and administrative | 182.3M | 196.9M | 116.2M | 103.6M | 63.6M | 38.3M | 24.2M | 20.1M | 9.99M | 6.32M |
| Operating income | -378.5M | -368.0M | -201.5M | -195.2M | -150.4M | 25.3M | -96.8M | -74.0M | -34.7M | -21.7M |
| Depreciation and amortization | 13.2M | 12.5M | 11.0M | 11.0M | 9.05M | 7.08M | 2.88M | 2.37M | 3.18M | 1.29M |
| EBITDA | -365.3M | -355.6M | -190.5M | -184.2M | -141.4M | 32.4M | -93.9M | -71.6M | -31.6M | -20.4M |
| Interest expense | 8.57M | 10.2M | 20.2M | 36.1M | 57.6M | 4.98M | 1.61M | 1.65M | 1.63M | 253.2K |
| Income before tax | -561.7M | -462.5M | -310.6M | -359.6M | -213.8M | 15.3M | -64.8M | -13.8M | -36.4M | -21.9M |
| Income tax | -2.42M | -33.5M | -2.01M | -473.0K | -6.27M | -36.0M | -896.0K | 36.3M | -1.70M | 0 |
| Net income | -559.3M | -429.0M | -308.6M | -359.1M | -203.5M | 9.13M | -60.9M | -45.8M | -34.7M | -21.9M |
| Earnings per share, basic | -1.33 | -1.46 | -1.34 | -2.56 | -1.92 | 0.13 | -1.21 | -1.24 | -1.30 | -1.46 |
Balance sheet
| Line | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 23.6M | 36.7M | 56.5M | 22.5M | 158.7M | 20.4M | 82.4M | 39.0M | 71.9M | 31.7M |
| Short-term investments | 26.3M | 90.2M | 256.4M | 297.0K | 441.0K | 1.11M | 97.4M | 0 | 0 | |
| Receivables | 24.5M | 18.7M | 15.5M | 14.5M | 4.36M | 3.93M | 2.98M | 2.62M | 732.0K | 394.2K |
| Inventory | 9.98M | 8.11M | 1.83M | 3.36M | 2.90M | 0 | 0 | 0 | 0 | 0 |
| Current assets | 96.4M | 173.0M | 86.2M | 67.6M | 179.6M | 29.7M | 89.7M | 141.0M | 73.9M | 32.6M |
| Property, plant and equipment | 52.0M | 41.3M | 31.9M | 29.9M | 24.4M | 19.3M | 12.7M | 7.25M | 2.28M | 2.44M |
| Goodwill | 80.3M | 79.5M | 43.6M | 38.3M | 38.3M | 38.3M | 41.5M | 20.6M | 24.0M | 24.0M |
| Total assets | 472.8M | 694.8M | 535.8M | 557.6M | 624.1M | 431.6M | 401.6M | 343.5M | 141.5M | 92.6M |
| Accounts payable | 47.5M | 27.4M | 24.7M | 27.6M | 13.8M | 9.91M | 8.28M | 1.34M | 1.66M | 2.15M |
| Current liabilities | 327.9M | 139.5M | 96.5M | 115.2M | 61.6M | 79.0M | 76.1M | 30.9M | 9.56M | 5.48M |
| Long-term debt | 19.1M | 110.6M | 92.3M | 199.1M | 223.1M | 5.21M | 47.1M | 4.39M | 8.83M | 4.43M |
| Total debt | 134.5M | 237.6M | 169.4M | 290.8M | 233.3M | 5.21M | 47.3M | 9.23M | 12.1M | 4.80M |
| Total liabilities | 494.5M | 616.7M | 395.1M | 524.9M | 416.6M | 225.0M | 315.1M | 202.6M | 32.8M | 25.8M |
| Shareholders' equity | -21.7M | 78.1M | 140.7M | 32.8M | 207.5M | 206.6M | 86.5M | 140.9M | 108.7M | 66.8M |
| Shares outstanding | 419.3M | 294.8M | 229.8M | 140.5M | 106.2M | 70.4M | 50.4M | 36.9M | 26.7M | 15.0M |
Cash flow
| Line | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -293.9M | -281.8M | -159.5M | -173.0M | -111.8M | -99.2M | -70.9M | -42.1M | -28.8M | -16.5M |
| Capital spending | -13.7M | -8.87M | -37.6M | -11.4M | -11.2M | -11.0M | -6.86M | -3.71M | -591.0K | -931.3K |
| Free cash flow | -307.5M | -290.7M | -197.1M | -184.4M | -123.0M | -110.2M | -77.8M | -45.8M | -29.4M | -17.4M |
| Cash from investing | -28.5M | 79.8M | -39.9M | -38.2M | -21.2M | -16.5M | -17.5M | 12.6M | -10.6M | -503.5K |
| Cash from financing | 311.7M | 181.3M | 174.2M | 78.9M | 326.0M | 53.7M | 131.7M | -3.35M | 79.6M | 43.6M |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | |||||
| Share buybacks | 403.5M | 217.2M | -55.0M | 56.5M | 61.4M | 57.9M | -15.6M | 1.75M | 72.1M | 37.7M |
| Change in cash | -13.0M | -19.8M | -24.3M | -132.6M | 192.9M | -62.0M | 43.4M | -32.9M | 40.2M | 26.6M |
Cap table
Built by 6ix from Sorrento Therapeutics, Inc.’s releases
- Common shares
- 551,281,154
- Fully diluted
- 551,281,154
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 551,281,154 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 551,281,154 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Jane Hsiao Other companies: OPKO Health, Inc. (Vice Chairman and Chief Technical Officer · Since at least Feb 9, 2007); Cocrystal Pharma, Inc. (Director · Mar 17, 2014 – Sep 21, 2018 · Past); PROLOR Biotech Inc (Director · Jul 23, 2009 – Aug 29, 2013 · Past); Non-Invasive Monitoring Systems, Inc. (Interim CEO, Director · Oct 30, 2008 – Dec 21, 2018 · Past); Asensus Surgical Inc (Director · Aug 24, 2007 – Jun 30, 2021 · Past); Protalix BioTherapeutics, Inc. (de) (Director · Dec 31, 2006 – Jan 31, 2007 · Past); Ivax Corp (Vice Chairman and CTO, Director · Jan 26, 2006 – Jan 26, 2006 · Past) | Director · Jan 25, 2010 – Feb 6, 2012 · Past |
| Jerome Zeldis Other companies: NexGel, Inc (Director · Since at least Mar 8, 2021); PTC Therapeutics, Inc. (Director · Since at least Jun 19, 2013); Soligenix, Inc. (Board Director · Since at least Jun 22, 2011); NexImmune, Inc. (Executive VP of Research & Dev · Feb 11, 2021 – Apr 5, 2022 · Past); MetaStat Inc (Director · Oct 11, 2017 – Oct 11, 2017 · Past); Beyond Air, Inc. (Director · Mar 14, 2017 – Mar 14, 2017 · Past); Streamex Corp. (Director · Jul 20, 2015 – Jul 14, 2020 · Past) | See Remarks · Aug 12, 2016 – Nov 26, 2018 · Past |
| Robin L. Smith Other companies: Matinas BioPharma Holdings, Inc. (Director · Feb 13, 2025 – Nov 4, 2026 · Past); Cycurion, Inc. (Director · Jan 11, 2022 – Jan 11, 2022 · Past); Celularity Inc. (Director · Jul 16, 2021 – Jun 14, 2023 · Past); ServiceSource International Inc (Director · Feb 27, 2020 – May 20, 2020 · Past); Rockwell Medical, Inc. (Director · Jun 6, 2019 – Jun 6, 2019 · Past); Emmaus Life Sciences, Inc. (Director · May 8, 2019 – May 8, 2019 · Past) | Director · Dec 16, 2019 – Sep 3, 2021 · Past |
| Glenn L Halpryn Other companies: Niagen Bioscience, Inc. (Director · May 20, 2010 – Jul 6, 2015 · Past); Olenox Industries Inc. (Director · Apr 23, 2010 – Apr 23, 2010 · Past); Fluent, Inc. (Director · Oct 30, 2009 – Jan 11, 2010 · Past); Castle Brands Inc (Director · Oct 11, 2008 – Mar 26, 2015 · Past); BioCardia, Inc. (CEO, Director · Oct 30, 2007 – Aug 29, 2008 · Past) | Director · Feb 5, 2010 – Feb 6, 2012 · Past |
| Elizabeth Czerepak Other companies: TransCode Therapeutics, Inc. (CFO, Director · Since at least Oct 6, 2025); Delcath Systems, Inc. (DIRECTOR · Since at least Feb 14, 2020); Scilex Holding Company (See Remarks · Nov 10, 2022 – Jan 17, 2023 · Past); Spectrum Pharmaceuticals Inc (Director · Jun 19, 2019 – Jun 18, 2020 · Past) | EVP & Chief Financial Officer · Nov 15, 2021 – May 18, 2022 · Past |
| Jaisim Shah Other companies: Semnur Pharmaceuticals, Inc. (See Remarks, Director · Since at least Sep 22, 2025); Scilex Holding Company (See Remarks, Director · Nov 10, 2022 – Dec 18, 2024 · Past); Facet Biotech Corp (SVP, Chief Business Officer · Dec 9, 2008 – Dec 9, 2008 · Past); PDL BioPharma Inc (SVP, Mktg & Bus. Affairs · Jan 9, 2006 – Apr 28, 2008 · Past) | Director · Sep 9, 2013 – Aug 30, 2021 · Past |
| Miranda Toledano Other companies: Entera Bio Ltd. (Chief Executive Officer and Board Member · Since at least Jan 1, 2022); Journey Medical Corporation (Director · Since at least Nov 16, 2021); NexGel, Inc (Director · Sep 9, 2021 – Aug 17, 2023 · Past); Compass Therapeutics, Inc. (Director · Jun 25, 2021 – Jun 25, 2021 · Past) | EVP-Corporate Development · Sep 16, 2016 – Sep 16, 2016 · Past |
| David Deming Other companies: Phio Pharmaceuticals Corp. (Director · Since at least Feb 19, 2025); Better for You Wellness Inc. (Director · Since at least Sep 30, 2021); Albany Molecular Research Inc (Director · Jun 15, 2016 – Aug 31, 2017 · Past) | Director · Jul 11, 2016 – Sep 15, 2017 · Past |
| Edgar Lee Other companies: Oaktree Specialty Lending Corporation (See Remarks · Oct 17, 2017 – Dec 15, 2017 · Past); Oaktree Strategic Income Corporation (See Remarks · Oct 17, 2017 – Dec 15, 2017 · Past); Charter Communications, Inc. (Director · Jan 18, 2011 – May 1, 2013 · Past) | Director · Dec 9, 2019 – Jun 15, 2020 · Past |
| Antonius Schuh Other companies: Cardiff Oncology, Inc. (CEO, Director · Jan 23, 2012 – Jan 4, 2016 · Past); Precipio, Inc. (Director · May 20, 2009 – Feb 18, 2014 · Past) | Chairman and CEO, Director · Feb 16, 2010 – Feb 16, 2010 · Past |
All 24 people
| Person | Seat |
|---|---|
| Henry Ji Other companies: Semnur Pharmaceuticals, Inc. (Executive Chairman, Chief Executive Officer and President · Since at least Nov 5, 2026); Scilex Holding Company (Executive Chairman, Chief Executive Officer and President · Since at least Jan 30, 2026) | Chairman, President and CEO · Since at least Nov 5, 2026 |
| William S Marth Other companies: Teligent Inc (Director · Feb 15, 2021 – Jul 21, 2021 · Past); Albany Molecular Research Inc (President and CEO, Director · Dec 31, 2015 – Aug 31, 2017 · Past) | Director · Jul 11, 2016 – Jul 11, 2016 · Past |
| Yue Alexander Wu Other companies: Semnur Pharmaceuticals, Inc. (Director · Since at least Sep 22, 2025); Scilex Holding Company (Director · Since at least Sep 22, 2023) | Director · Aug 1, 2016 – Aug 30, 2021 · Past |
| Daniel J Levitt Other companies: Neurogene Inc. (Director · Mar 6, 2014 – May 14, 2018 · Past) | Director · Jan 30, 2014 – Jan 30, 2014 · Past |
| Mark Durand Other companies: Radius Health, Inc. (Chief Commercial Officer · Apr 1, 2014 – Jun 5, 2014 · Past) | EVP & CFO · Mar 7, 2014 – Apr 29, 2015 · Past |
| Michael Scott Salka Other companies: Armata Pharmaceuticals, Inc. (Chief Executive Officer, Director · Aug 5, 2015 – Apr 1, 2017 · Past) | Director · Feb 23, 2012 – Jan 23, 2014 · Past |
| Steve Zaniboni Other companies: Cardiff Oncology, Inc. (Former CFO · Jan 23, 2012 – Apr 21, 2016 · Past) | Director · Nov 29, 2010 – Nov 29, 2010 · Past |
| David Ritchie Webb | Director · Sep 6, 2012 – Oct 29, 2013 · Past |
| Dean Ferrigno | Chief Accounting Officer · May 15, 2017 – Feb 28, 2018 · Past |
| Diane D S Tang-Liu | Director · Feb 23, 2012 – Jul 20, 2012 · Past |
| Douglas O Ebersole | Director · Aug 6, 2014 – Jul 11, 2016 · Past |
| John Waldheim | Executive Director, Government Affairs · Since at least Nov 5, 2026 |
| Scott Schaus | Chief Technology Officer · Since at least Nov 5, 2026 |
| Tammy Reilly | Director · May 18, 2022 – May 18, 2022 · Past |
Log in to ask 6ix AI your own questions about Sorrento Therapeutics, Inc.